Diagnostic biomarkers for active tuberculosis: progress and challenges

dc.creatorNogueira, Betânia M. F.
dc.creatorKrishnan, Sonya
dc.creatorDuarte, Beatriz Barreto
dc.creatorPereira, Mariana Araújo
dc.creatorQueiroz, Artur T. L .
dc.creatorEllner, Jerrold J.
dc.creatorSalgame, Padmini
dc.creatorScriba, Thomas J.
dc.creatorSterling, Timothy R.
dc.creatorGupta, Amita
dc.creatorAndrade, Bruno B.
dc.date2023-01-03T19:02:44Z
dc.date2023-01-03T19:02:44Z
dc.date2022
dc.date.accessioned2023-09-26T23:04:10Z
dc.date.available2023-09-26T23:04:10Z
dc.identifierNOGUEIRA, Betânia M. F. et al. Diagnostic biomarkers for active tuberculosis: progress and challenges. EMBO Molecular Medicine, v. 14, p. 1-13, 2022.
dc.identifier1757-4684
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/56301
dc.identifier10.15252/emmm.202114088
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8886476
dc.descriptionNational Institute of Health. Programa de Pesquisa Intramural da Fundação Oswaldo Cruz. Conselho Nacional de Desenvolvimento Científico e Tecnológico Desenvolvimento (CNPq).
dc.descriptionTuberculosis (TB) is a leading cause of morbidity and mortality from a single infectious agent, despite being preventable and curable. Early and accurate diagnosis of active TB is critical to both enhance patient care, improve patient outcomes, and break Mycobacterium tuberculosis (Mtb) transmission cycles. In 2020 an estimated 9.9 million people fell ill from Mtb, but only a little over half (5.8 million) received an active TB diagnosis and treatment. The World Health Organization has proposed target product profiles for biomarker- or biosignature-based diagnostics using point-of-care tests from easily accessible specimens such as urine or blood. Here we review and summarize progress made in the development of pathogen- and host-based biomarkers for active TB diagnosis. We describe several unique patient populations that have posed challenges to development of a universal diagnostic TB biomarker, such as people living with HIV, extrapulmonary TB, and children. We also review additional limitations to widespread validation and utilization of published biomarkers. We conclude with proposed solutions to enhance TB diagnostic biomarker validation and uptake.
dc.formatapplication/pdf
dc.languageeng
dc.publisherEMBO Press
dc.rightsopen access
dc.subjectTuberculose ativa
dc.subjectBiomarcadores
dc.subjectBiomarcadores de diagnóstico
dc.subjectTuberculose
dc.subjectActive TB
dc.subjectBiomarkers
dc.subjectDagnostic biomarkers
dc.subjectTuberculosis
dc.subjectBiomarcadores
dc.subjectTuberculose
dc.titleDiagnostic biomarkers for active tuberculosis: progress and challenges
dc.typeArticle


Este ítem pertenece a la siguiente institución